Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Autor:
Seung Joon Kim, Mi Hyun Kim, Cheol-Kyu Park, Kye Young Lee, Shin Yup Lee, Jeong Seon Ryu, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon, Taeyun Kim, Sei Hoon Yang, Jeong Eun Lee, Yoon Soo Chang, Chan Kwon Park, Sung Yong Lee, Tae-Won Jang, Chang-Min Choi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 17, Pp 5809-5822 (2021)
Cancer Medicine, Vol 10, Iss 17, Pp 5809-5822 (2021)
Objectives The optimal sequence for the administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for treating non‐small cell lung cancer (NSCLC) is still unclear. This study aimed to evaluate the efficacy of seque
Autor:
Yusuke Ono, Ryohei Katayama, Noriko Yanagitani, Ken Uchibori, Makoto Nishio, Satoru Kitazono, Ryo Ariyasu, Ryohei Yoshida, Yusuke Mizukami, Mika Tsukahara, Takaaki Sasaki, Kazuma Kiyotani, Yuichi Ishikawa, Naoya Fujita, Hironori Ninomiya
Publikováno v:
Cancer Science
Osimertinib is a third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) that is effective in treating both naïve and T790M‐mutated EGFR‐TKI‐resistant non–small cell lung cancer patients. The EGFR C797S mut
Publikováno v:
FEBS Open Bio
FEBS Open Bio, Vol 10, Iss 7, Pp 1288-1294 (2020)
FEBS Open Bio, Vol 10, Iss 7, Pp 1288-1294 (2020)
We previously demonstrated that a deficiency of natural antibodies against CD25, Mucin 1 (MUC1), and vascular endothelial growth factor receptor 1 (VEGFR1) could contribute to high risk of non‐small cell lung cancer (NSCLC). This study was designed
Autor:
Kenji Kimura, Eiichi Morii, Izumi Nagatomo, Takeshi Harada, Yasushi Shintani, Shinji Matsumoto, Akira Kikuchi
Publikováno v:
Cancer Science
Lung adenocarcinoma is the most common histological type of lung cancer and is classified into adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IA). Atypical adenomatous hyperplasia (AAH) lesions are
Autor:
Koshiro Ohtsubo, Seiji Yano, Hiroko Ikeda, Sachiko Arai, Shinji Takeuchi, Naohiro Yanagimura, Chiaki Suzuki, Kaname Yamashita, Kenji Kita, Sakiko Otani, Masaya Tamura, Hiro Takahashi, Azusa Tanimoto, Koji Fukuda, Akihiro Nishiyama, Isao Matsumoto
Publikováno v:
Cancer Science
Patient‐derived xenograft (PDX) models are a useful tool in cancer biology research. However, the number of lung cancer PDX is limited. In the present study, we successfully established 10 PDX, including three adenocarcinoma (AD), six squamous cell
Autor:
Hiroshige Yoshioka, Hiroshi Tanaka, Tatsuro Fukuhara, Terufumi Kato, Kazuhiko Yamada, Hiroshi Sakai, Miyako Satouchi, Kazuhiko Nakagawa, Masao Ichiki, Takashi Seto, Kazuo Kasahara, Makoto Nishio, Shi Rong Han, Toshiaki Takahashi, Takashi Shimamoto, Kazuo Noguchi
Publikováno v:
Cancer Science
Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD‐1), has been shown to improve overall survival (OS) in patients with previously treated advanced non–small‐cell lung cancer (NSCLC) with programmed death ligand 1 (PD
Autor:
Keunchil Park, Hiroshi Nokihara, Yuichiro Kaneko, Akira Inoue, Katsuyuki Kiura, Koji Takeda, Masashi Shimazaki, Tomoki Nakagawa, Kentaro Takeda, Hidetoshi Hayashi, Chun-Ming Tsai, Sang We Kim, James Chih-Hsin Yang, Makoto Nishio, Koichi Azuma, Masahiro Fukuoka, Rio Akazawa, Satoshi Morita, Jin Hyoung Kang, Haruyasu Murakami, Takashi Seto, Kazuhiko Nakagawa
Publikováno v:
Cancer Science
Epidermal growth factor receptor (EGFR)-activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non-small-cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once-daily, oral, EGFR TKI that inhibits
Autor:
Tomohiro Sakakibara, Masayuki Yamamoto, Shinya Ohkouchi, Keiko Nakayama, Tsutomu Tamada, Hisatoshi Sugiura, Akira Koarai, Akira Watanabe, Toshihiro Nukiwa, Akira Inoue, Toshiaki Kikuchi, Yoichi Matsubara, Taizou Hirano, Tetsuya Niihori, Yoko Aoki, Kunio Matsumoto, Naoki Tode, Tatsuma Okazaki, Masakazu Ichinose
Publikováno v:
Cancer Science
Lung cancer accompanied by somatic activating mutations in the epidermal growth factor receptor (EGFR) gene, which is associated with a significant clinical response to the targeted therapy, is frequently found in never-smoking Asian women with adeno